changing the paradigm for cancer treatment
Cybrexa Therapeutics is developing an entirely new class of therapeutics that directly targets the tumor microenvironment.
Cybrexa was founded by physician-scientists and an experienced management team that has built numerous successful life sciences ventures. We are an oncology-focused platform technology company that enables antigen-independent targeting of tumors and metastases with deep tissue penetration for small molecule anti-cancer drugs. We’re passionate about bringing new treatment options to help more cancer patients live longer, more fulfilling lives.MORE ABOUT US
it all begins with alphalexTM
Cybrexa alphalex is a tumor targeting platform that powers new applications and combinations of existing cancer therapeutics. Using an elegant approach for targeted intracellular drug delivery independent of surface antigens, alphalex selectively delivers powerful anticancer agents directly into tumor cells.